Site priorities
Which sites to open, with protocol-specific rationale.
ONCOLOGY ENROLLMENT INTELLIGENCE
We help oncology sponsors decide which sites to open and what they can realistically enroll—then identify protocol-matched patient opportunities around selected sites.

For biotech and clinical-development teams worldwide. Independent intelligence, alongside your clinical team and CRO.
Which sites to open, with protocol-specific rationale.
A defined time window, an estimated range and the assumptions behind it.
Site-level opportunity views and patient-level leads for authorized clinical review.
Solutions
Start with your protocol and the stage your trial has reached.
01 / BEFORE SITE SELECTION
Which sites should we open—and what can they realistically enroll?
Turn an existing protocol into a prioritized site plan. We combine patient opportunity, competition, investigator context and operating evidence to explain where the trial can work and what enrollment to expect.
02 / AFTER SITES ARE SELECTED
Where are the patient opportunities around the sites we already selected?
Apply protocol criteria to permitted clinical and real-world evidence around selected or active sites. We deliver both aggregate opportunity views and patient-level leads that authorized clinical teams can verify and act on.

How It Works
Company
We bring evidence together around the enrollment question—not around ownership of one dataset. The aim is a usable site plan or patient-opportunity handoff that complements sponsor and CRO work.
Kevin leads company strategy, product and commercial relationships. Allen leads technology and clinical-intelligence methodology. Each engagement identifies its analysts, reviewers and sponsor or clinical-team handoff. Additional expertise is agreed where needed.
Meet the team ↗
ONCOLOGY ENROLLMENT INTELLIGENCE
Tell us whether you are choosing sites or working with sites already selected. Start with non-confidential context; we will define the relevant deliverable and access arrangements together.